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ABSTRACT 
Background: Fibromyalgia is a complex poly-symptomatic condition. These symptoms include chronic widespread 
musculoskeletal pain. No one treatment has been found to address all the symptoms of this syndrome. Pharmacological 
interventions which have provided improvement in the symptoms of the disease include duloxetine, lidocaine infusion and 
tramadol. The aim of this essay is to compare the analgesic efficacy and quality of life of fibromyalgia patients following 
the use of duloxetine or lidocaine in their management. Evidence derived from analysis of existing literature will be used 
to decide a preference for either of the two interventions. Methods: An electronic search of Medline, EMBASE, Nice 
evidence, Trip database, Cochrane Library and Science Citation Index from inception to April 2016 and update to July 
2018 was done using the key words below. Google scholar search engine and manual search of relevant studies from 
bibliographies in literature was also employed. Quality of included Randomized control trials (RCTs) were assessed using 
the JADAD score (I - V). Most relevant studies were included in this review. These were independently retrieved by the 
two investigators and were discrepancy existed, resolved by consensus. Discussion: Evidence abound on the safety and 
efficacy of duloxetine in the management of fibromyalgia and it promises to be the ideal pharmaco-therapeutic agent for 
the treatment of fibromyalgia. However, some cases may be refractory to it, necessitating the use of other agents like 
lidocaine. There is a dearth of good quality randomized control trials in literature to support the safety and efficacy of 
lidocaine monotherapy in the management of fibromyalgia patients. Conclusion: This article explores evidence regarding 
use of duloxetine and lidocaine infusion in management of fibromyalgia. Although the potentials of lidocaine infusion in 
the treatment of this condition is acknowledged, clinical evidence from this review is insufficient to fairly compare the 
efficacy of duloxetine with lidocaine infusion in the management of patients with fibromyalgia.Well-designed RCTs are 
required to compare the qualities of these 2 interventions in management of fibromyalgia  
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INTRODUCTION 
 
Pain is a subjective experience; it is what the patient 
says hurts[1]. It is a common cause of suffering, 
disability and economic loss in the community. The 
annual incidence of chronic pain was estimated at 8.3% 
according to the National Pain Audit in United 
Kingdom, concluded in 2012 [2]. That report also 
showed that 11% of adults and 8% of children in the 
United Kingdom suffer moderate to severe chronic 
pain.  
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The prevalence of chronic pain in the United Kingdom, 
derived from 7 population studies in a meta-analysis by 
Fayaz et al. (2016) is43.5% (95% CI, 38.4-48.6%) [3].  
Chronic pain is more prevalent with increase in age, 
female sex, poor housing and heavy manual 
employment [2]. 
Pain may manifest as a symptom of ongoing tissue 
pathology or injury. However, it may also represent a 
disease entity, serving no useful purpose; persisting 
beyond the healing period. As a disease, pain adversely 
affects the physical, psychosocial and spiritual well-
being of patients. Fibromyalgia is a syndrome 
characterized by chronic widespread musculoskeletal 
pain, reduced pain threshold with hyperalgesia and 
allodynia affecting more than 65% of defined tender 
points (trigger points) in the body. Associated features 
include chronic fatigue, sleep disturbance, irritable 
bowel syndrome and cognitive dysfunction [4]. This 
condition is also commonly associated with 
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psychological states such as depression and anxiety; 
and stress-related psychiatric disorder (post-traumatic 
stress disorder[5]. It is seen in 1-3% of the population, 
affecting more females than males (ratio of 2:1)[6]. 
Fibromyalgia is commonly noticed between the 3rd and 
6th decades of life. Fibromyalgia is a complex poly-
symptomatic condition which lacks one treatment that 
addresses all the symptoms. The European league 
against rheumatism (EULAR), recommends that 
optimal treatment of fibromyalgia requires a 
multimodal approach comprising non-pharmacological 
and pharmacological modalities with active patient 
participation[7]. Evidence-based guidelines for the 
management of fibromyalgia (by EULAR, American 
pain society and German association of pain therapy) 
did not include lidocaine infusion therapy and some 
large randomized control trials that assessed 
duloxetine, pregabalin and milnacipran[7-9]. However, 
a Cochrane collaboration review suggests 
‘’combination pharmacotherapy’’ in the management 
of this condition [10]. Cognitive behavioural therapy 
(CBT), aerobic exercises, heated pool therapy 
(balneotherapy), relaxation techniques, and 
hypnotherapy have shown varying degrees of success 
in the treatment of fibromyalgia. Pharmacological 
interventions which have provided improvement in the 
symptoms of the disease include norepinephrine 
/serotonin re-uptake inhibitors, selective serotonin re-
uptake inhibitors, tricyclic anti-depressants, serotonin 
antagonists, lidocaine infusion and tramadol [7-
9,11].Duloxetine tablets are taken daily(per oral)by the 
patient on medical instruction and require strict 
compliance whereas, lidocaine may be administered as 
a monitored intravenous infusion in the hospital once 
every 2-3 months. Duloxetine is recommended for the 
treatment for fibromyalgia. [7-9] High attrition rates 
seen in studies that utilized duloxetine therapy (shown 
below) may be attributed to its undesirable side effects. 
This presents a risk of poor drug compliance by 
patients which could be addressed by periodic 
(monitored) administration of lidocaine infusion. In 
recalcitrant fibromyalgia that is refractory to 
duloxetine, or if a patient demonstrates adverse 
reaction to duloxetine, lidocaine infusion therapy (if 
shown to be as good or better than duloxetine) may be 
employed to achieve good clinical outcome. Therefore, 
this review will utilize evidence from clinical research 
to compare the analgesic efficacy and quality of life of 
patients following the use of duloxetine or lidocaine 
infusion in the management of fibromyalgia. The 
objective of this review is to decide from critical 
analysis of existing literature, a justification for the 
preference of either intervention in the management of 
this condition. 
 
METHODOLOGY 
Electronic search of NICE Evidence, Trip database, 
Cochrane Library, AMED, BNI, CINAHL, EMBASE, 
HBE, HMIC, MEDLINE, PsychoINFO, Google 
scholar and Science Citation Index from inception till 
2016 and updated to July 2018 was done using the 
search key words above. Manual search of relevant 
studies from bibliographies in literature were also 
performed. Articles were excluded if they were 
ongoing trials or written in a language other than 
English. No article compared effects of Duloxetine 
with Lidocaine infusion in the management of 
fibromyalgia,this prevented any direct comparison of 
the two interventions. Quality of included studies were 
assessed using JADAD scale (I – V). [12] Most 
relevant studies with JADAD scores III and above 
were included in this review. These were 
independently retrieved by the two investigators and 
any discrepancy was resolved by consensus. The 
JADAD scale was adopted because it is easy to use, 
reliable and validated quality assessment tool that has 
good correlation with risk of bias of studies. [13]Forty-
two RCTs assessed the qualities of Duloxetine alone or 
as combination regimen in the treatment of 
fibromyalgia. Only 10 placebo-controlled RCTs 
evaluated the effects of duloxetine as monotherapy for 
fibromyalgia. Seven of these RCTs assessed the 
analgesic efficacy of duloxetine or quality of life of the 
participants as primary outcomes (which are relevant to 
this review) and were therefore considered. The best 4 
out of 6 placebo-controlled RCTs on Duloxetine 
monotherapy in fibromyalgia that had JADAD scores 
III and above (by consensus) were selected for detailed 
discussion. There was no placebo-controlled RCT on 
efficacy of lidocaine infusion monotherapy for 
fibromyalgia in literature. Three out ofthe 4 RCTs that 
employed lidocaine infusion as combined-therapy for 
fibromyalgia had JADAD score III and above and were 
discussed in this review. Because of dearth of RCTs 
evaluating lidocaine infusion monotherapy in treatment 
of fibromyalgia, two retrospective studies that 
employed this treatment regimen were also included in 
this review. Studies that employed lidocaine that were 
excluded include; case reports (n=2), case series (n=3), 
audit (n= 1) and surveys (n= 2). 
Literature review and critical analysis 
There is no known cure for fibromyalgia [7].Treatment 
aims to relieve symptoms, improve function and 
quality of life. Pain relief following intervention in this 
condition, can be assessed by verbal rating scale 
(VRS), numerical rating scale (NRS), visual analogue 
scale (VAS) and brief pain inventory (BPI)[9]. Some 
studies have used an electronic pain diary which is 
 
Asian Pac. J. Health Sci., 2019; 6(3):36-42                                                  e-ISSN: 2349-0659, p-ISSN: 2350-0964 
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Okubuiro and Ebirim                   Asian Pacific Journal of Health Sciences, 2019;6(3):36-42                     Page  38 
www.apjhs.com       
 
credited with a ‘more accurate real-time measurement 
of pain’[14].A manual tender point assessment of pain 
threshold with dolorimetry has also been utilized to 
measure response to treatment. Similar uni-
dimensional, self-administered tools have been used to 
generally evaluate fatigue and quality of life in some 
studies.[9] However, function and quality of life in the 
management of fibromyalgia are mostly assessed by a 
self-reported, validated fibromyalgia impact 
questionnaire (FIQ). The FIQ measures; physical 
functioning, work status, depression, anxiety, morning 
tiredness, pain, stiffness, fatigue and well-being during 
the preceding week [9]Although the pathogenesis of 
fibromyalgia remains poorly understood, evidence 
suggests central sensitization as an important 
pathophysiological mechanism[15]. Pain perception is 
a dynamic experience which results from a relationship 
between faciltatory and inhibitory endogenous 
modulation systems. The descending inhibitory 
systems involve the serotoninergic, noradrenergic and 
opioidergic pathways which are activated by higher 
centres in the brain.[16] Julien et al, showed a deficit of 
endogenous pain inhibitory systems in fibromyalgia 
but not in chronic back pain and therefore suggested 
that treatment of fibromyalgia should aim at 
stimulating the activity of those endogenous 
systems.[17]Duloxetine is recommended for the 
management of fibromyalgia. [7,9]  Duloxetine is a 
balanced selective serotonin and noradrenergic 
reuptake inhibitor which was primarily licensed as an 
antidepressant. It gained approval for the management 
of fibromyalgia by the United States Food and Drug 
Agency in 2008.[18] Duloxetine inhibits the re-uptake 
of serotonin and nor-adrenaline in the central nervous 
system thereby enhancing the activities of these 
neurotransmitters via the descending spinal inhibitory 
pain pathway. The activation of this pathway hinders 
the transmission of nociceptive stimuli through the 
‘pain gates’ at the dorsal horn of the spinal cord to the 
brain. It also exerts analgesia via sodium ion channel 
blockade in the CNS. It is usually administered orally 
at a dose of 60-120mg daily[18] Some associated side 
effects of duloxetine include nausea, dry mouth and 
dizziness; this is usually transient and reduced by 
graded increase in dosing of the drug. Arnold et al 
(2004) conducted a double-blind multi-centre 
randomized control trial which compared duloxetine 
with placebo in the treatment of fibromyalgiain 18 out-
patient research centres including 207 patients with a 
mean age of 49 years in the United States of America. 
[19] Compared to the placebo-treated patients, 
duloxetine-treated patients showed significantly 
improved overall FIQ scores(p=0.027), brief pain 
inventory (0.004), number of tender points (0.002) and 
better quality of life. While duloxetine-treated female 
patients (n=92/184) recorded significant improvement 
in most efficacy measures, their male counterparts 
(n=12/23) showed no significant improvement in any 
of the outcome measures. Although the female to male 
ratio in that study (8:1) suggests a higher female 
preponderance of this condition than earlier reported, 
the relatively insignificant number of the male 
participants (12%), impairs the generalizability of their 
findings to the male or entire population.  The short 
duration of the study could not enable the 
determination of the long-term efficacy of duloxetine 
in the treatment of fibromyalgia. The study raises 
ethical concerns as placebo-treated patients received no 
other form of analgesia over the 12 weeks duration of 
the trial. Also, the FIQ which measured outcomes 
retrospectively may not have accurately represented the 
state of the patients after a period of one week. The 
power of the study (90%) was estimated to detect a 
treatment group difference of 1.4 points in pain 
severity; this may be considered much less than the 
general acceptable difference of 2.0 points and exposes 
the study to type 2 error. Although the study was 
powered to accommodate 200 patients, about 40% of 
the participants could not complete the trial. This 
grossly impairs the statistical power of the study and 
adversely affects its clinical significance. Another 
multi-centre randomized placebo controlled, double 
blind parallel group study confirmed the efficacy and 
safety of duloxetine 60mg daily and 60mg B.D in 
women with fibromyalgia.[20] The study showed that 
these two doses of duloxetine, provided significantly 
better brief pain inventory average pain severity score 
(p<0.001) than placebo. Patients in the duloxetine 
groups also had significantly better improvement in 
FIQ scores, patient global impression of improvement 
and quality of life measures. The effects of duloxetine 
on pain, mood and major depressive disorder were 
independent. A total of108 women (39%) withdrew 
from the study, this was greater than the attrition rate 
(30%) allowable in the design. This also adversely 
affects the power of the study to accurately detect 
response to the interventions. While a significantly 
greater number of patients withdrew in the duloxetine 
groups (n=52) due to adverse side effects, another great 
number from the placebo group did so due to lack of 
efficacy. Similar number of patients in the three groups 
were withdrawn from the study due to non-compliance. 
Also, side effects such as nausea, dry mouth, anorexia 
and constipation and somnolence were significantly 
greater in the duloxetine groups. These were more 
pronounced in the duloxetine 60mg B.D group, 
although this group benefitted from significant 
improvement in tender point assessments. The high 
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incidence of side effects may have been due to the use 
of one dose of duloxetine in each of the treatment 
groups throughout the study duration, instead of a 
graded increase in dose over the same period. The 
small treatment group differencein pain scores, 
accepted as significant (1.2 points) may have yielded 
unreliable results. Finally, this study was conducted on 
women only therefore cannot be generalized to the 
male or entire population of both genders. With the aim 
to determine the long-term efficacy and safety of 
duloxetine in the management of fibromyalgia, Russel 
et al. (2008) conducted anothermulti-centre 
randomized double-blind control trial that primarily 
measured pain relief using brief pain inventory (BPI). 
[21] Compared to placebo, patients who received 
duloxetine 120mg/day reported significant analgesia at 
3 and 6 months respectively. Both duloxetine 
30mg/day and 60mg/dayprovided significantly greater 
improvements compared to placebo in FIQ total scores, 
clinical global impressions-severity scores and multi-
dimensional fatigue inventory scores. Quality of life 
measured by EuroQoL questionnaire-5 dimension was 
significantly better in the treatment groups compared to 
placebo at 6 months. The insignificant difference in 
adverse events between the placebo and treatment 
groups is suggestive of the safety of these doses of 
duloxetine in the treatment of fibromyalgia. Reasons 
for the high drop-out rate (37.3%), which was 
comparable in all the groups (p=0.645) were mainly 
adverse effects (Duloxetine group) or lack of efficacy 
(Placebo group) and patient decision (both groups). 
This reduces the power of the study (80%), which was 
designed to evaluate 140 participants in each group. It 
would have been more appropriate to consider a drop-
out rate of 40% in the study design based on similarly 
high attrition rates from previous studies[16, 17]. 
Although the study was meant to include both sexes 
diagnosed with fibromyalgia from 18 years and above, 
most of the participants were women (94.8%); also 
suggesting a higher female preponderance than 
estimated. Both sexes recorded similar improvements 
following treatment with duloxetine, however, the 
relatively insignificant number of males (5.2%), also 
implies that the findings of the study cannot be 
generalized to the male population. Number needed to 
treat (NNT) was mentioned in the study design but 
unfortunately, it was not calculated in any of the 
treatment groups. Although it could be assumed that 
duloxetine provided significantly better analgesia in 
fibromyalgia after 6 months of treatment, this cannot 
be categorically applied to the numerous secondary 
outcome measures since the study was not powered to 
assess such.Similarly, Murakami et al (2015) 
conducted another multi-centre RCT to assess the 
efficacy and safety of duloxetine among 393 patients 
diagnosed with fibromyalgia. [22]They reported 
significant improvement in pain relief (p=0.04) and 
quality of life measures (p= 0.02) among duloxetine 
group compared with placebo group. However, 
improvement in quality of life is not surprising as 
duloxetine is also licensed for treatment of depression, 
which is a condition often associated with 
fibromyalgia. Attrition rate of 15% noticed in the 
duloxetine group was mostly attributed to adverse drug 
reaction. This could explain the reports of poor drug 
compliance often noticed with use of duloxetine in this 
condition. [19, 20]Non-drug therapies are 
recommended as first line treatment for fibromyalgia 
[6] and participants on exercise therapy and cognitive 
behavioural therapy prior to this study were not 
excluded. The confounding effect of this inclusion on 
the final outcome could not be ascertained in this 
study. And, sponsorship of that trial by an interested 
party (Drug company) increases the risk of bias which 
impairs its credibility.A systematic review by Sultan et 
al.(2008) involving 6 clinical trials with 1,696 patients, 
confirmed the efficacy and safety of duloxetine in 
painful diabetic neuropathy and fibromyalgia pain[23]. 
NNT of 6 was reported using duloxetine in both 
conditions. They reported more withdrawals in the 
duloxetine groups (15%) than the placebo (8%). Side 
effects were significantly higher in the treatment 
groups than placebo and infrequent serious adverse 
events were noted. They also reported that doses 
greater than 60mg/day did not provide additional pain 
relief but caused more withdrawals due to side effects. 
However, the statistical significance of this review is 
challenged by few numbers of randomized clinical 
trials involved.Patients with fibromyalgia have lowered 
thermal and mechanical pain thresholds, high response 
and altered temporal summation to pain stimuli. 
Attempts at its pharmacological management are aimed 
at interference with the central processing of pain. Such 
interference may be achieved by pain inhibition 
modulatory drugs which activate serotoninergic and 
nor-adrenergic systems[17, 18]. Pain processing can 
also be altered by systemic administration of drugs 
which inhibit the excitatory pathway such as 
lidocaine[24]. Lidocaine is a local anaesthetic which is 
also used as an anti-arrhythmic agent. It is a sodium 
channel blocker which has been used successfully to 
treat neuropathic pain[21].  It exerts its membrane 
stabilizing effect by reversibly binding to intracellular 
sodium ion channels, obstructing influx of ions thereby 
preventing depolarization of such tissues. This effect is 
experienced by all excitable tissues and accounts for 
the side effects experienced following systemic 
administration. Lidocaine is administered at a dose of 
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2-5mg/kg body weight by intravenous infusion over 
30-60 minutes[26, 27]. Its associated side effects 
include hypotension, hypertension, tachycardia, 
arrhythmia, headache and dizziness[26]. Tinnitus, 
circum-oral tingling, convulsion and coma are signs of 
avoidable local anaesthetic toxicity. This may be 
treated with intralipid emulsion infusion with 
cardiopulmonary resuscitation, if necessary. Lidocaine 
is contraindicated in persons with cardiac disease, 
abnormal ECG and electrolyte imbalance. Careful 
patient selection, strict adherence to safe doses and 
close patient monitoring are key to reduction of 
adverse side effects.Lidocaine has been used 
successfully in the management of fibromyalgia. In 
2002, a retrospective study reported efficacy and 
adverse effects using intravenous lidocaine infusion in 
the management of 106 patients with fibromyalgia[28]. 
The results showed that pain and psychosocial 
measures (using numerical rating scale), improved 
significantly after treatment with5mg/kg of lidocaine. 
Two major (pulmonary oedema and supraventricular 
tachycardia) and 42 minor side effects were reported. 
Hypotension was mostly noticed (16%) amongst the 
patients who suffered adverse effects. None of the 
participants suffered any long-term sequalae. However, 
the sensitivity of the report is affected by the 
retrospective assessment methods employed. Absence 
of blinding exposed the study to bias thereby 
diminishing its credibility. Lack of control prevents a 
fair assessment of the true potentials of the 
intervention. Schafranski et al. (2009) confirmed the 
efficacy and safety of lidocaine infusion in the 
management of 23 fibromyalgia patients[11]. 
Significant improvement in FIQ scores was noticed on 
the 5th (p=0.020) and 30th (p=0.01) days post 
intervention. Pain relief (measured with visual 
analogue scale) also significantly improved on the 5th 
p=0.01) and 30th (p=0.05) days post treatment. No side 
effects were reported in this study. However, lack of 
randomization and control hampers the credibility of 
this report. Conversely, a randomized, double blind, 
comparative clinical trial which was conducted later, 
reported no difference in pain intensity or number of 
tender points between patients who had lidocaine 
infusion with amitriptyline and those who that received 
amitriptyline alone in the management of 
fibromyalgia[27]. However, compared to the baseline 
values, there was significant improvement in the two 
parameters earlier mentioned in the two treatment 
groups. They also reported no significant reduction in 
fatigue, subjective oedema or morning stiffness after 
treatment in both groups. But, there was no power 
calculation. The study did not state the allowable β-
error (usually 0.2). There was no mention of the 
primary outcome; standard assessment of which would 
have been vital in the calculation of sample size. There 
was no mention of any pilot or similar studies from 
which significance of difference in outcome measures 
could have been derived. The small sample size (n=14 
per group) and these methodological concerns arguably 
exposed this trial to a high probability of type 2 error. 
Amitriptyline has earlier been used for the treatment of 
fibromyalgia[7]. Its combination with lidocaine impairs 
a fair assessment of the true potentials of the later in 
the management of fibromyalgia. The credibility of the 
study is further eroded by non-mention of the statistical 
tools used in the analysis of the results. Ethical 
concerns are raised by non-exclusion of patients with 
cardiac/ECG abnormalities and lack of ECG 
monitoring of the patients who received lidocaine 
infusion. A similar study, later conducted by the same 
authors, found no improvement in pain intensity, no 
significant difference in plasma serotonin, 
norepinephrine or dopamine concentration following 
lidocaine infusion in fibromyalgia patients using the 
same regimen above[24]. Also, this study had no 
power calculation and the small sample size (n=15 per 
group), exposed it to high chances of β-error thereby 
diminishing its statistical relevance. This later study 
was also challenged by similar methodological 
controversies as its predecessor. Another RCT by 
Giraldes et al. (2016) comparing intravenous lidocaine 
injection combined with amitriptyline and intravenous 
injection of saline (placebo) combined with 
amitriptyline showed no meaningful impact of thefirst, 
compared to the later intervention in the treatment of 
fibromyalgia patients. [29] Patients who received 
lidocaine injection with amitriptyline reported similar 
reduction in pain intensity as those who had saline 
injection with amitriptyline and, there was no 
difference in their side effect profiles. However, 
amitriptyline is a tricyclic anti-depressant that is also 
used in treatment of fibromyalgia and other chronic 
pain conditions. It interferes with the true effects of 
lignocaine there by significantly confounding this 
study. Also, liberal consumption of paracetamol and 
tramadol by both groups (though comparable), hinders 
fair assessment of analgesic efficacy and side effects of 
the interventions in the two groups. Any effects noticed 
would be shared by these potent analgesics. These 
challenges the credibility of the study and diminishes 
acceptability of its findings. A retrospective study by 
Hung-Jun et al. (2013) affirmed the analgesic efficacy 
of lidocaine in patients with fibromyalgia.[30] This 
study reviewed 55 patients whose pains were mostly 
refractory to other treatments. Although significant 
difference in pain scores (measured with the visual 
analogue scale and brief pain inventory) were noted, 
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the p-values were not reported. The assessment of the 
effects of lidocaine based on data retrieved from 
patients’ charts reduced the accuracy and sensitivity of 
the report. Lack of blinding and control precluded the 
objective assessment of the intervention and further 
erodes the clinical importance of the study. 
CONCLUSION 
Fibromyalgia is a complex poly-symptomatic condition 
of uncertain aetiology and pathogenesis.[4, 15] This 
enigmatic disease seems to have more female 
preponderance than previously reported.[6, 19] Its 
optimal management requires a multi-modal, multi-
disciplinary approach involving pharmacological and 
non-pharmacological interventions.[7]Studies included 
in this review employed various pain assessment tools 
although most of them affirm the analgesic efficacy of 
duloxetine and lignocaine respectively, in treatment of 
fibromyalgia. Retrospective, patient-administered, 
investigator-administered and third-party data 
collection methods employed in different studies re-
affirm marked methodological heterogeneity observed 
in this review. Duloxetine, a novel drug with dual 
mechanisms of action, is licensed for the management 
of fibromyalgia.[18] It is a sodium channel blocker 
which stabilizes neuronal membranes thereby reducing 
the cellular hyper-excitability observed in patients with 
fibromyalgia. It also acts centrally by activating the 
spinal and supra-spinal pain inhibitory pathways. With 
abundant evidence of its safety and efficacy in the 
management of fibromyalgia and few adverse effects, 
it promises to be the ideal pharmaco-therapeutic agent 
for the treatment of this condition.[23] However, some 
cases may be refractory to it necessitating the use of 
other agents like lidocaine. [26]Lidocaine, also a 
sodium channel blocker and neuronal cell membrane 
stabilizer, is recommended in the management of other 
neuropathies[25]. Controversies surrounding incidence 
of its side-effects and possible toxicity can be resolved 
by careful patient selection, close patient monitoring 
and strict adherence to safe doses[11, 26]. There is 
dearth of good quality randomized control trials in 
literature to support its safety and efficacy in the 
management of fibromyalgia patients. Evidence 
supporting its use in this condition is mainly derived 
from case reports and retrospective studies.[11, 28, 30] 
There is no study in current literature which directly 
compares duloxetine and lidocaine infusion in the 
management of fibromyalgia syndrome. Available 
clinical evidence from literature is insufficient to fairly 
compare the efficacy of duloxetine with lidocaine 
infusion in the management of patients with 
fibromyalgia. 
RECOMMENDATIONS 
Following the dearth of standard clinical research on 
the use of lidocaine infusion in the management of 
fibromyalgia, more randomized controlled trials that 
are sufficiently powered (80%,β-error: 0.02) are 
required to assess its effects on patients. Adequate 
sample size for such robust studies may be derived 
from pilot studies of previous clinical trials with good 
methodologies. Some patients may show resistance or 
intolerance to the side effects of some recommended 
drugs. Therefore, comparative studies of duloxetine 
and lidocaine infusion in the treatment of this condition 
are recommended to determine their relative safety and 
potency and widen the treatment options. Such double-
blind studies should be meticulously designed with 
adequate statistical power and sample size estimation. 
The results obtained should be analysed with standard 
statistical tools to ensure its credibility. 
In designing studies which use duloxetine in the 
management of this condition, sample size estimation 
should accommodate up to 40% attrition rate. High 
drop-out rates previously experienced might also be 
reduced by provision of incentives to the participants. 
More hospital-based assessments of the interventions 
are recommended to reduce the error of improper 
assessment which may occur in patients’ self-
administered assessments. Validated, ‘real-time’ 
outcome measures such as visual analogue scale should 
be encouraged in the assessment of analgesic efficacy 
of the interventions to ensure uniformity and more 
accurate representation of the effects of the treatments. 
LIMITATIONS 
Inclusion of only studies reported in English language 
might have inadvertently excluded relevant clinical 
trials that might have been performed on the subject 
but in other languages. Dearth of good quality clinical 
trials comparing duloxetine versus lidocaine or 
lidocaine alone versus placebo, adversely affects direct 
or indirect comparison of effects of the two 
interventions in management of fibromyalgia. 
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